NeuroPace (NPCE) Competitors

NeuroPace (NASDAQ:NPCE) and Enovis (NYSE:ENOV) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, community ranking, risk, analyst recommendations, media sentiment, earnings and profitability.

Do analysts prefer NPCE or ENOV?

NeuroPace presently has a consensus price target of $15.50, suggesting a potential upside of 31.02%. Enovis has a consensus price target of $58.00, suggesting a potential upside of 73.94%. Given Enovis' higher probable upside, analysts clearly believe Enovis is more favorable than NeuroPace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroPace	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Enovis	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Does the media favor NPCE or ENOV?

In the previous week, NeuroPace had 10 more articles in the media than Enovis. MarketBeat recorded 14 mentions for NeuroPace and 4 mentions for Enovis. Enovis' average media sentiment score of 0.87 beat NeuroPace's score of 0.48 indicating that Enovis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroPace	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Enovis	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders and institutionals hold more shares of NPCE or ENOV?

78.8% of NeuroPace shares are held by institutional investors. Comparatively, 98.4% of Enovis shares are held by institutional investors. 22.2% of NeuroPace shares are held by insiders. Comparatively, 2.7% of Enovis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Which has higher valuation and earnings, NPCE or ENOV?

NeuroPace has higher earnings, but lower revenue than Enovis. NeuroPace is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroPace	$84.31M	4.60	-$32.96M	-$0.84	-14.08
Enovis	$2.15B	0.89	-$33.26M	-$13.95	-2.39

Is NPCE or ENOV more profitable?

Enovis has a net margin of -5.95% compared to NeuroPace's net margin of -36.74%. Enovis' return on equity of 4.39% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroPace	-36.74%	-205.41%	-28.29%
Enovis	-5.95%	4.39%	2.80%

Which has more volatility and risk, NPCE or ENOV?

NeuroPace has a beta of 2.03, suggesting that its stock price is 103% more volatile than the S&P 500. Comparatively, Enovis has a beta of 1.71, suggesting that its stock price is 71% more volatile than the S&P 500.

Does the MarketBeat Community favor NPCE or ENOV?

Enovis received 1 more outperform votes than NeuroPace when rated by MarketBeat users. Likewise, 66.04% of users gave Enovis an outperform vote while only 62.96% of users gave NeuroPace an outperform vote.

Company	Underperform	Outperform
NeuroPace	Outperform Votes 34 62.96%	Underperform Votes 20 37.04%
Enovis	Outperform Votes 35 66.04%	Underperform Votes 18 33.96%

Summary

NeuroPace and Enovis tied by winning 9 of the 18 factors compared between the two stocks.